Ultrasound-based micro-/nanosystems for biomedical applications

H Huang, Y Zheng, M Chang, J Song, L **a… - Chemical …, 2024 - ACS Publications
Due to the intrinsic non-invasive nature, cost-effectiveness, high safety, and real-time
capabilities, besides diagnostic imaging, ultrasound as a typical mechanical wave has been …

Heating technology for malignant tumors: A review

HP Kok, ENK Cressman, W Ceelen… - International Journal …, 2020 - Taylor & Francis
The therapeutic application of heat is very effective in cancer treatment. Both hyperthermia,
ie, heating to 39–45° C to induce sensitization to radiotherapy and chemotherapy, and …

[HTML][HTML] An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?

JS Hopstaken, JGR Bomers, MJP Sedelaar, M Valerio… - European Urology, 2022 - Elsevier
Context Focal therapy is a promising, minimally invasive strategy to selectively treat
localized prostate cancer. A previous systematic review indicated that there is growing …

High-intensity focused ultrasound: a review of mechanisms and clinical applications

VS Bachu, J Kedda, I Suk, JJ Green, B Tyler - Annals of biomedical …, 2021 - Springer
Abstract High Intensity Focused Ultrasound (HIFU) is an emerging and increasingly useful
modality in the treatment of cancer and other diseases. Although traditional use of …

Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year …

D Reddy, M Peters, TT Shah, M van Son, MB Tanaka… - European Urology, 2022 - Elsevier
Background Focal therapy aims to treat areas of cancer to confer oncological control whilst
reducing treatment-related functional detriment. Objective To report oncological outcomes …

MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study

B Ehdaie, CM Tempany, F Holland, DD Sjoberg… - The Lancet …, 2022 - thelancet.com
Background Men with grade group 2 or 3 prostate cancer are often considered ineligible for
active surveillance; some patients with grade group 2 prostate cancer who are managed …

Structured population-based prostate-specific antigen screening for prostate cancer: the European Association of Urology position in 2019

G Gandaglia, P Albers, PA Abrahamsson, A Briganti… - European urology, 2019 - Elsevier
Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe.
Screening in asymptomatic men (aged 55–69 yr) using prostate-specific antigen (PSA) is …

Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry

TT Shah, M Peters, D Eldred-Evans, S Miah, T Yap… - European urology, 2019 - Elsevier
Background Focal cryotherapy can be used to treat patients with clinically significant
nonmetastatic prostate cancer to reduce side effects. Objective Early-medium-term cancer …

Medium‐term oncological outcomes in a large cohort of men treated with either focal or hemi‐ablation using high‐intensity focused ultrasonography for primary …

A Stabile, C Orczyk, F Hosking‐Jervis… - BJU …, 2019 - Wiley Online Library
Objective To report medium‐term oncological outcomes in men receiving primary focal
treatment with high‐intensity focused ultrasonography (HIFU) for prostate cancer (PC a) …

Contemporary treatments in prostate cancer focal therapy

M Ahdoot, AH Lebastchi, B Turkbey… - Current opinion in …, 2019 - journals.lww.com
Prostate cancer focal therapy is an attractive option for well-selected patients because of its
low complication profile; however, long-term oncologic outcome is still lacking and early …